Eurican Lmulti Suspension for Injection

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae

Pieejams no:

Boehringer Ingelheim Animal Health UK Ltd

ATĶ kods:

QI07AB01

SNN (starptautisko nepatentēto nosaukumu):

Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae

Zāļu forma:

Suspension for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Dogs

Ārstniecības joma:

Inactivated Bacterial Vaccine

Autorizācija statuss:

Authorized

Autorizācija datums:

2015-12-10

Produkta apraksts

Revised: September 2020
AN: 01797/2019
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Lmulti Suspension for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (1ml) of suspension contains:
ACTIVE SUBSTANCES:
Inactivated_ Leptospira interrogans _serogroup_ _ and serovar Canicola
strain 16070
......................................................................Activity
acc. to Ph. Eur.447*
Inactivated_ Leptospira interrogans _serogroup and serovar _
_Icterohaemorrhagiae
strain16069
.......................................................................Activity
acc. to Ph. Eur.447*
Inactivated _Leptospira interrogans _serogroup and serovar_
_Grippotyphosa
strain Grippo Mal 1540
..........................................................Activity
acc. to Ph. Eur.447*
*

80% protection in hamsters
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Opalescent and homogenous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to:
-
prevent mortality, clinical signs, infection, bacterial excretion,
renal carriage and
renal
lesions
caused
by
_Leptospira_
interrogans
serogroup
Icterohaemorrhagiae
serovar Icterohaemorrhagiae
-
prevent mortality* and clinical signs, reduce infection, bacterial
excretion, renal
carriage and renal lesions caused by _ Leptospira_ interrogans
serogroup Canicola
serovar Canicola.
-
prevent mortality*, and reduce clinical signs, infection, bacterial
excretion renal
carriage and renal lesions caused by _Leptospira_ kirschneri serogroup
Grippotyphosa
serovar Grippotyphosa.
Revised: September 2020
AN: 01797/2019
Page 2 of 5
-
prevent
mortality,
clinical
signs,
renal
infection,
bacterial
excretion,
renal
carriage
and
renal
lesions
caused
by
_Leptospira_
_interrogans_
serogroup
Icterohaemorrhagiae serovar Copenhageni.**
Onset of immunity: 2 weeks after the second injection of the primary
v